Baxter International Inc.

Valuation Analysis

About the Company

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuti

Baxter International Inc. Stock at a Glance

Baxter International Inc. (BAX) is currently trading at $20.86 with a market capitalization of $10.8B. The 52-week range spans from $15.73 to $31.76; the current price is 34.3% below the yearly high. Year-over-year revenue growth stands at +2.9%.

💰 Dividend

Baxter International Inc. pays an annual dividend of $0.20 per share, representing a yield of 0.96%. The payout ratio stands at 307.69%. The elevated payout ratio reflects a mature dividend policy.

📊 Analyst Rating

12 analysts rate Baxter International Inc. (BAX) on consensus: Hold. The average price target is $21.54, implying +3.27% from the current price. Analyst price targets range from $17.00 to $40.00.

Baxter International Inc.: The Investment Case in Detail

Baxter International Inc. (BAX) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Revenue growth has slowed to just 2.9%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 12.96% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

At a PEG of 36.68, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 9.65x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (12.96%), higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Baxter International Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.